Severe toxicity following supratherapeutic co‑ingestion of duloxetine and dexzopiclone in a young patient with major depressive disorder: a case report
- 1Department of Neurology, The Second People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, No.282 Wusi Road, Gulou District, Fuzhou, 350003 People’s Republic of China
- 2Department of Emergency, The Second People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, 350003 People’s Republic of China
Abstract
A 23-year-old female with major depressive disorder (MDD), non-suicidal self-injury and generalized somatic pain was treated with duloxetine hydrochloride enteric-coated capsules, quetiapine fumarate tablets, and aripiprazole orally disintegrating tablets, with significant pain relief. Dexzopiclone tablets were added for insomnia, and all medications were kept by her mother. Despite compliance with medication, the patient had persistent suicidal ideation and secretly ingested 4500 mg duloxetine and 63 mg dexzopiclone on February 18, 2021. She was rushed to hospital 3.5 h later and received emergency treatment including oxygen inhalation, gastric lavage and high-dose vitamin B6/C infusion. Combined with psychological suggestion and cognitive therapy, she recovered and was discharged 12 days later. At the 4.5-year follow-up (September 2025), the patient had discontinued lurasidone and quetiapine, both of which were started during index hospitalization; she demonstrated normal daily functioning with no recurrent suicidal ideation or self-injury. To our knowledge, severe toxicity from co-ingestion of supratherapeutic doses of duloxetine and dexzopiclone has been rarely documented; this report details the clinical management and differential diagnosis strategies for this rare drug-combination toxicity.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13256-026-06736-y.
Related
- Pilot study of duloxetine plus aerobic exercise for pain and depressive symptoms in knee osteoarthritis.
- Severe upper gastrointestinal corrosive injury following intentional muriatic acid (HCl) ingestion: a case report
- Fatal acute respiratory distress syndrome following intentional ingestion of glyphosate-surfactant herbicide (Glyfield®): a case report and literature review
- Effect of Duloxetine on the Perioperative Anxiety Status and Stress Response Following Total Hip Arthroplasty: A Randomized Controlled Trial
- Delayed pancytopenia following ingestion of wild mushrooms consistent with Hypholoma fasciculare: A case report
BibTeX
@article{jinmin2026severe,
title = {{Severe toxicity following supratherapeutic co‑ingestion of duloxetine and dexzopiclone in a young patient with major depressive disorder: a case report}},
author = {Wang Jinmin and Lin Jushan and Lin Min and Liao Yunhai and Zheng Chongwen},
journal = {Journal of Medical Case Reports},
year = {2026},
month = nov,
doi = {10.1186/s13256-026-06736-y},
url = {https://doi.org/10.1186/s13256-026-06736-y},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Severe toxicity following supratherapeutic co‑ingestion of duloxetine and dexzopiclone in a young patient with major depressive disorder: a case report
AU - Wang Jinmin
AU - Lin Jushan
AU - Lin Min
AU - Liao Yunhai
AU - Zheng Chongwen
PY - 2026
DA - 2026/11/06
JO - Journal of Medical Case Reports
DO - 10.1186/s13256-026-06736-y
UR - https://doi.org/10.1186/s13256-026-06736-y
AB - A 23-year-old female with major depressive disorder (MDD), non-suicidal self-injury and generalized somatic pain was treated with duloxetine hydrochloride enteric-coated capsules, quetiapine fumarate tablets, and aripiprazole orally disintegrating tablets, with significant pain relief. Dexzopiclone tablets were added for insomnia, and all medications were kept by her mother. Despite compliance with medication, the patient had persistent suicidal ideation and secretly ingested 4500 mg duloxetine and 63 mg dexzopiclone on February 18, 2021. She was rushed to hospital 3.5 h later and received emergency treatment including oxygen inhalation, gastric lavage and high-dose vitamin B6/C infusion. Combined with psychological suggestion and cognitive therapy, she recovered and was discharged 12 days later. At the 4.5-year follow-up (September 2025), the patient had discontinued lurasidone and quetiapine, both of which were started during index hospitalization; she demonstrated normal daily functioning with no recurrent suicidal ideation or self-injury. To our knowledge, severe toxicity from co-ingestion of supratherapeutic doses of duloxetine and dexzopiclone has been rarely documented; this report details the clinical management and differential diagnosis strategies for this rare drug-combination toxicity. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13256-026-06736-y.
SN - 1752-1947
ER -